Cite

HARVARD Citation

    Siemers, E. et al. (2016). Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients. Alzheimer's & dementia. 12 (2), pp. 110-120. [Online]. 
  
Back to record